DrugRisk Update: Studies Warn of Risperdal Side Affects in Children
New York, NY (PRWEB) November 25, 2013 -- The medication safety advocates at DrugRisk.com are announcing updated information for parents whose children have been prescribed the antipsychotic drug Risperdal. A recent study shows higher risks of diabetes in children taking the drug*, in addition to prior concerns of abnormal breast growth**.
DrugRisk is a free resource providing the latest studies, warnings, recalls and legal news to those using popular prescription drugs. Patients can talk with their doctor about potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
Risperdal is an atypical antipsychotic drug from Johnson & Johnson subsidiary Janssen Pharmaceuticals approved to treat schizophrenia, bipolar disorder and autism. However, the company recently pled guilty to promoting it for unapproved treatments in hundreds of thousands of children***.
The resource center has added studies linking the drug to gynecomastia, or abnormal breast growth in children that can be accompanied by milk production**. As the condition is non-reversible, it often requires surgery to correct.
Now, DrugRisk has learned of a new study from Vanderbilt University which found antipsychotics like Risperdal may also triple the risk of type-2 diabetes in children*. The study followed more than 43,000 children, finding the risks may increase in just one year of use.
Johnson & Johnson has already paid settlements to patients filing a Risperdal lawsuit alleging they needed surgery after the drug caused abnormal breast growth****.
Anyone affected by diabetes or abnormal breast growth after taking Risperdal is urged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of drug injury cases, DrugRisk only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Risperdal and other drugs, or to speak with a lawyer.
*Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
**Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
***Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
****Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618
Chris Schroeder, DrugRisk, http://www.DrugRisk.com, +1 888-415-1859, [email protected]
Share this article